PEDIATRICS Vol. 53 No. 6 June 1974, pp. 929-937
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frasier, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frasier, S. D.

A Review of Growth Hormone Stimulation Tests in Children

S. Douglas Frasier M.D.1

1 Department of Pediatrics, University of Southern California School of Medicine and the Los Angeles County-University of Southern California Medical Canter, Los Angeles

No suggested screening test meets all of the criteria set for such a procedure. The minimum incidence of a positive response in normal children detected in a single blood sample after diethylstilbestrol, sleep or exercise is approximately 70%. This is higher than that observed when a single sample is obtained following oral glucose. While both sleep and exercise are physiologic stimuli, the former may be quite inconvenient unless an outpatient facility staffed with appropriate personnel is available. An exercise test employed in the office may well be the best screening procedure for the practicing physician.

The optimal criteria for a definitive test of growth hormone function are also not met by any single stimulus. Insulin-induced hypoglycemia, arginine infusion, intramuscular glucagon and oral 1-DOPA are all useful procedures. None alone discriminate completely between the normal and the growth hormone-deficient child. Despite potential hazards, insulin-induced hypoglycemia remains the standard against which other stimuli are judged. Arginine and 1-DOPA appear to be equally effective. The literature contains insufficient data to allow adequate evaluation of intramuscular glucagon alone, and the results of combined propranolol-glucagon stimulation, while promising, require confirmation. Because of an inconstant and/or small magnitude of response leading to results which are difficult to interpret, the use of glucose, pyrogen, vasopressin and ACTH are not adequate tests of growth hormone function. Bovril® is a satisfactory stimulus for those children who will take it.

Those factors which modify the growth hormone response must be considered in evaluating the results of stimulation tests. Blunted responses should be interpreted with extreme caution in the obese child. A fasting growth hormone concentration ge 7 ng/ml is presumptive evidence of intact growth hormone function regardless of the subsequent response to stimulation. It is essential that patients be euthyroid in order to interpret the results of growth hormone function tests. Physiologic glucocorticoid replacement therapy should not confuse the interpretation of results. Whether or not pretreatment with sex steroids is worthwhile in the routine evaluation of children for suspected growth hormone deficiency is an open question.

Although it is agreed that the definitive diagnosis of growth hormone deficiency depends on the demonstration of failure to respond to two stimuli, which two are most satisfactory is not settled. The sequential administration of arginine and insulin on the same day appears to limit significantly the incidence of false-positive laboratory diagnoses of growth hormone deficiency.

The significance of intermediate values in response to stimulation remains unclear. Caution should be exercised in assigning a child to the category of partial growth hormone deficiency. This question must be answered ultimately by the response to HGH therapy in the individual patient.

Finally, several points should be kept in mind. All of the tests described depend on the detection and quantitation of immunologically active HGH and biological activity is not necessarily associated with the material(s) being measured. Since many of the stimuli used in the evaluation of growth hormone function are clearly pharmacologic, the physiological significance of the response to such stimuli must be interpreted with caution. The best current evidence suggests that all of the stimuli described act through an intact hypothalamus and pituitary. Differentiation between hypothalamic and pituitary sites of defective growth hormone function awaits the availability of growth hormone-releasing factor(s).

Submitted on November 21, 1973
Accepted on January 31, 1974




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
N. Giri, D. L. Batista, B. P. Alter, and C. A. Stratakis
Endocrine Abnormalities in Patients with Fanconi Anemia
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2624 - 2631.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
R Ayling
More guidance on growth hormone deficiency
J. Clin. Pathol., February 1, 2004; 57(2): 123 - 125.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. S. MartÍnez, H. M. Domené, M. G. Ropelato, H. G. Jasper, P. A. Pennisi, M. E. Escobar, and J. J. Heinrich
Estrogen Priming Effect on Growth Hormone (GH) Provocative Test: A Useful Tool for the Diagnosis of GH Deficiency
J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4168 - 4172.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. C. Hoeck, P. Vestergaard, P. E. Jakobsen, J. Falhof, and P. Laurberg
Diagnosis of Growth Hormone (GH) Deficiency in Adults with Hypothalamic-Pituitary Disorders: Comparison of Test Results Using Pyridostigmine Plus GH-Releasing Hormone (GHRH), Clonidine Plus GHRH, and Insulin-Induced Hypoglycemia as GH Secretagogues
J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1467 - 1472.
[Abstract] [Full Text]

Home page
 Endocr. Rev.Home page
S. M. Shalet, A. Toogood, A. Rahim, and B. M. D. Brennan
The Diagnosis of Growth Hormone Deficiency in Children and Adults
Endocr. Rev., April 1, 1998; 19(2): 203 - 223.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
J.-C. Carel, J.-P. Tresca, M. Letrait, J.-L. Chaussain, Y. Lebouc, J.-C. Job, and J. Coste
Growth Hormone Testing for the Diagnosis of Growth Hormone Deficiency in Childhood: A Population Register-Based Study
J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2117 - 2121.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. G. Rosenfeld and M. D.
Is Growth Hormone Deficiency a Viable Diagnosis?
J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 349 - 351.
[Full Text] [PDF]

Home page
 PediatricsHome page
Committee on Drugs and Committee on Bioethics
Considerations Related to the Use of Recombinant Human Growth Hormone in Children
Pediatrics, January 1, 1997; 99(1): 122 - 129.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
G.L. Spadoni, S. Cianfarani, S. Bernardini, F. Vaccaro, C. Galasso, M.L. Manca Bitti, F. Costa, and B. Boscherini
Twelve-hour Spontaneous Nocturnal Growth Hormone Secretion in Growth Retarded Patients
Clinical Pediatrics, October 1, 1988; 27(10): 473 - 478.
[Abstract] [PDF]